ORIGINAL ARTICLE

Comprehensive analysis of *CDKN2A* (p16^{INK4A}/p14^{ARF}) and *CDKN2B* genes in 53 melanoma index cases considered to be at heightened risk of melanoma

K Laud, C Marian, M F Avril, M Barrois, A Chompret, A M Goldstein, M A Tucker, P A Clark, G Peters, V Chaudru, F Demenais, A Spatz, M W Smith, G M Lenoir, B Bressac-de Paillerets, French Hereditary Melanoma Study Group*

J Med Genet 2006;43:39–47. doi: 10.1136/jmg.2005.033498

See end of article for authors' affiliations

Correspondence to:
Dr B Bressac-de Paillerets,
Service de Génétique,
Institut Gustave Roussy, 39
rue Camille Desmoulins,
94805 Villejuif Cedex,
France; bressac@igr.fr

Revised version received
23 May 2005
Accepted for publication
24 May 2005
Published Online First
3 June 2005

Objective: Comprehensive analysis of the 9p21 locus including the *CDKN2A*, *ARF*, and *CDKN2B* genes in 53 individuals from melanoma index cases considered to be at heightened risk of melanoma.

Methods and Results: Using a combination of DNA sequencing, gene copy number by real time quantitative PCR, linkage analysis, and transcript analysis in haploid somatic cell hybrids, we found no evidence for germline alteration in either coding or non-coding domains of *CDKN2A* and *CDKN2B*. However, we identified a p14^{ARF} exon 1β missense germline mutation (G16D) in a melanoma-neural system tumour syndrome (CMM+NST) family and a 8474 bp germline deletion from 196 bp upstream of p14^{ARF} exon 1β initiation codon to 11233 bp upstream of exon 1α of p16^{INK4A} in a family with five melanoma cases. For three out of 10 families with at least three melanoma cases, the disease gene was unlinked to the 9p21 region, while linkage analysis was not fully conclusive for seven families.

Conclusions: These data reinforce the hypothesis that *ARF* is a melanoma susceptibility gene and suggest that germline deletions specifically affecting p14^{ARF} may not be solely responsible for NST susceptibility. Predisposition to CMM+NST could either be due to complete disruption of the *CDKN2A* locus or be the result of more complex genetic inheritance. In addition, the absence of any genetic alteration in 50 melanoma prone families or patients suggests the presence of additional tumour suppressor genes possibly in the 9p21 region, and on other chromosomes.

Linkage analysis has implicated a gene or genes on human chromosome 9p21 in the inherited predisposition to cutaneous malignant melanoma (CMM).¹ To date, three tumour suppressor genes have been identified in this region. *CDKN2A* and *CDKN2B*, which presumably arose by tandem duplication, encode structurally similar proteins, p16^{INK4A} and p15^{INK4b}, respectively, that function as inhibitors of the cyclin dependent kinases Cdk4 and Cdk6. However, the *CDKN2A* locus has the unusual capacity to encode completely distinct proteins from two alternatively spliced transcripts. Whereas the α transcript, comprising exons 1α, 2, and 3, encodes p16^{INK4A}, the smaller β transcript, comprising exons 1β, 2, and 3, specifies a protein designated p14^{ARF} because the exon 2 sequences are translated in an alternative reading frame relative to that used for p16^{INK4A}. Both p16^{INK4A} and p15^{INK4b} are able to cause G1 cell cycle arrest by inhibiting the phosphorylation of the retinoblastoma protein (Rb), while p14^{ARF} can arrest cells in both G1 and G2/M phases via its ability to inhibit MDM2 mediated destruction of the p53 tumour suppressor (reviewed in Sharpless and DePinho²).

Germline mutations of *CDKN2A* have been found in about 20–40% of families with multiple cases of melanoma and are located in both exon 1α and exon 2.³ In addition to germline mutations that impair the function of p16^{INK4A}, there have been several reports of alterations in non-coding regions of the gene that are clearly associated with melanoma susceptibility.^{4–8}

The status of p14^{ARF} as a tumour suppressor is less clear cut. Although germline mutations in *CDKN2A* exon 2 have the potential to impair both p16^{INK4A} and p14^{ARF}, a number

of studies have shown that removal of the amino acids encoded by exon 2 has no demonstrable effect on the known functions of p14^{ARF}.^{9–10} Conversely, other studies have suggested that mutations in exon 2 have the capacity to alter the subcellular localisation of p14^{ARF} as well as inactivating p16^{INK4A}.^{11–13} Moreover, germline alterations affecting p14^{ARF} and possibly p16^{INK4A} were detected in a subset of melanoma-neural system tumour (CMM+NST) families.^{14–16} Finally, germline mutations restricted to exon 1β have been detected in melanoma prone families or patients.^{17–18} Although highly suggestive that *ARF* is also a melanoma susceptibility gene, it has been difficult to obtain unequivocal proof based on functional impairment of p14^{ARF}. Perhaps the strongest evidence comes from mouse models in which p16^{INK4A} and p19^{ARF} genes have been selectively ablated. Mice lacking p16^{INK4A} alone (*INK4A*−/−; *ARF*+/+) did not develop melanomas, but when these knockout mice were crossed with mice lacking one copy of *ARF* (*INK4A*−/−; *ARF*+/−) they then had a propensity to develop melanomas.¹⁹ The effect of *ARF* haploinsufficiency in *INK4A* nullizygotes suggests that the reduced dosage of the *ARF* is sufficient to contribute to melanoma tumorigenesis in this background.

Interestingly, in one CMM+NST family, a large germline deletion encompassing *CDKN2A/ARF* and *CDKN2B* was identified.¹⁴ *CDKN2B* is located within about 30 kb centromeric

Abbreviations: CMM, cutaneous malignant melanoma; CMM+NST, melanoma-neural system tumour syndrome; dHPLC, denaturing high performance liquid chromatography; LFS, Li-Fraumeni syndrome; MPM, multiple primary melanoma; RQ-PCR, real time quantitative PCR

from *CDKN2A*. Although no specific germline mutations of the *CDKN2B* gene have yet been reported in familial melanoma kindreds,^{20–23} somatic point mutations in the *CDKN2B* gene were described in metastases of a patient affected by a melanoma²⁴ and in a primary melanoma.²⁵

These observations prompted us to undertake a comprehensive analysis of the 9p21 locus and its three genes, *CDKN2A*, *ARF*, and *CDKN2B*, in 53 index cases of melanoma prone families or patients. As well as screening for mutations in exons 1 α , 1 β , 2, and 3 of the *CDKN2A* gene, exons 1 and 2 of *CDKN2B*, and exon 2 of *CDK4*, we quantified *CDKN2A*, *ARF*, and *CDKN2B* gene copy number by real time quantitative PCR (RQ-PCR).²⁶ We also investigated the 5'UTR region of *CDKN2A* and screened for the IVS2-105A>G mutation in intron 2 of *CDKN2A* in all 35 index cases of CMM prone families and patients with multiple primary melanoma (MPM; group A). Finally, we performed linkage analyses in nine families with three melanoma cases (group A), and in six cases showing possible linkage to the 9p21 locus we used long range RT-PCR to search for differentially spliced transcripts that might be indicative of deep intronic mutations.

METHODS

Index case selection and control groups

The patients in this study were enrolled through the dermatology department of the Institut Gustave Roussy and different oncogenetics or dermatology departments from all over France.

Group A

This group comprised 36 cases of CMM, confirmed by pathological reports, that were considered to have a high probability of being hereditary based upon the following inclusion criteria: (a) families with at least three affected members ($n = 15$); (b) families with two melanoma cases, one of them being affected by at least two melanoma ($n = 7$); and (c) patients affected by at least three melanoma ($n = 14$). The patients tested were index cases in melanoma prone families or MPM patients. These probands had been pre-screened for *CDKN2A* (exon 1 α , 2, and 3) and *CDK4* exon 2 coding sequences, by either single strand conformation polymorphism (SSCP) or denaturing high performance liquid chromatography (dHPLC), and selected because found negative for germline mutation. In addition, the proband (FG7617) from an American multiplex melanoma family (family AN), ascertained by NCI, that included five patients with melanoma including three patients with multiple melanoma tumours, was selected for this study because 9p21 genotyping results were suspicious for a germline deletion. Two first cousins from family AN (FG7617 and FG7381) appeared homozygous for markers D9S974, D9S1748, and D9S171. Furthermore, the alleles that appeared homozygous in FG7381 were inherited from her mother (fig 1).

Group B

This group consisted of 12 melanoma cases, confirmed by pathological reports, with at least one second degree relative affected by a tumour from the CMM-NST syndrome (OMIM 155755).

Group C

These were five melanoma cases, confirmed by pathological reports, associated with families with cancer aggregations that do not strictly fit Li-Fraumeni syndrome (LFS) criteria but include paediatric tumours from the LFS spectrum (sarcoma or medulloblastoma).²⁷ The patients selected have no germline mutation in the *p53* gene coding sequence.

Control group

A total of 202 DNA samples were prepared from lymphocytes of patients without a familial cancer history and sequenced for *CDKN2A/ARF* (exon 1 α , 1 β , 2, and 3) and *CDK4* (exon 2).

dHPLC and sequence analyses

Genomic DNA was extracted from peripheral blood lymphocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. We screened for germline mutations in *CDKN2B* (exon 1 and 2), *ARF* (exon 1 β), and *CDKN2A* (exon 1 α , 2, and 3) and *CDK4* (exon 2) by dHPLC analysis, an automated heteroduplex detection method.^{28–30} PCR amplification was performed in a 20 μ l reaction with 100 ng genomic DNA, 1 $\times$ HotStar Taq DNA polymerase buffer including 1.5 mM MgCl₂ (Qiagen), 1 U of HotStar Taq DNA polymerase (Qiagen), and 4 pmol of each primer. For *CDKN2A* exon 1 α , 1.25 M betain (Sigma, St Louis, MO) was added to the PCR reaction mix. Primer sequences and dHPLC conditions are described in appendix A. For each sample, amplification reactions were performed using a touch down protocol: initial denaturation step at 95°C for 10 min; two cycles (30 s at 95°C, 30 s at 66°C, 30 s at 72°C); two cycles (30 s at 95°C, 30 s at 64°C, 30 s at 72°C); two cycles (30 s at 95°C, 30 s at 62°C, 30 s at 72°C); 40 cycles (30 s at 95°C, 30 s at 60°C, 30 s at 72°C). Heteroduplex analyses were carried out as described in Laud *et al.*³¹ Samples displaying abnormal profiles were subsequently sequenced on both strands with the Big Dye Terminator sequencing kit (Perkin Elmer Applied Biosystems, Foster City, CA) according to the manufacturer's instructions.

Screening of the *CDKN2A* promoter and the IVS2-105A>G deep intronic mutation was only performed on 36 index cases of the melanoma families (group A). We amplified the *CDKN2A* promoter region by PCR using the conditions described above. In order to screen for the IVS2-105A>G mutation (located in intron 2), the amplification reactions were performed using a touch down protocol with the following profile: initial denaturation step at 97°C for 15 min; six cycles (1 min at 97°C, 30 s at 68°C, 1 min at 72°C); six cycles (1 min at 97°C, 30 s at 66°C, 1 min at 72°C); six cycles (1 min at 97°C, 30 s at 64°C, 1 min at 72°C); 22 cycles (1 min at 97°C, 30 s at 60°C, 1 min at 72°C). PCR products were sequenced with the Big Dye Terminator sequencing kit (Applied Biosystems) according to the manufacturer's instructions. The primers used are described in appendix A.

RQ-PCR

The gene copy number of *CDKN2B*, *ARF* exon 1 β , and *CDKN2A* exon 1 α was estimated by real time quantitative PCR as described by Barrois *et al.*³² The primers and fluorogenic probes used are described in appendix A. PCR reactions were carried out in a volume of 50 μ l, using 25 μ l of TaqMan Universal PCR Master Mix (2 $\times$) (PE Biosystems, Foster City, CA) for all probes except the *ARF* exon 1 β probe for which we used 5 μ l of the TaqMan PCR Core Reagent Kit (10 $\times$) (PE Biosystems) complemented with 5% glycerol. Each PCR was performed with 1.25 U of Taq polymerase, 25 ng of DNA, 20 pmol of each primer, and 10 pmol of the fluorogenic probe. Each sample was analysed in triplicate. The thermal cycling conditions were as follows: activation of Taq polymerase at 95°C for 20 min and 40 cycles at 95°C for 15 s and 60°C for 1 min for *CDKN2A* and *ARF* and 65°C for *CDKN2B*. As positive controls, we used the HL60 cell line which is haploid at the 9p21 locus (*CDKN2B*, *ARF*, and *CDKN2A*) and the F615 cell line which is haploid for *ARF* only (kindly provided by Juliette Moor and Julia Newton-Bishop, CRUK Cancer Medicine Research Unit, St James's University Hospital, Leeds, UK).

Figure 1 (A) Pedigree of the CMM prone family AN (group A). Black symbols indicate melanoma affected patients and stripes indicate individuals with other types of cancers. The tumours and genotypes are indicated below the symbol and the number of melanomas is indicated in brackets. Stars indicate the patients who have been tested. (B) 9p21 locus map indicating microsatellite markers, p15^{INK4B}, p14^{ARF}, and p16^{INK4A} coding exons, and location of TaqMan probes. (C) 9p21 locus sequences of a normal control and of patient FG7617 showing the 8474 bp deletion breakpoints. (D) Mapping of the 8474 bp deletion breakpoints at 9p21 locus.

Characterisation of the germline deletion

The germline deletion was identified by long range PCR using peripheral blood lymphocyte DNA from patient no. 7617 and the GeneAmp XLPCR kit (Applied Biosystems). Primers were designed to amplify a large region (22.2 kb) encompassing the putative deletion (appendix A). The deletion breakpoints were then mapped by digesting the long range PCR product with *Bam*H1 and *Spe*I. Another set of primers was then designed to amplify a shorter fragment (8899 bp) which encompassed *ARF* exon 1β (appendix A). The different fragments obtained were gel purified with a Qiagen purification kit and sequenced using a Big Dye Terminator sequencing kit.

Linkage analyses and statistical methods

Linkage studies were performed on nine melanoma prone families, displaying at least three melanoma cases, as described by Auroy *et al.*³³ using four microsatellite markers on chromosome 9p21 (D9S736, D9S1749 (*CDKN2A*), D9S942, and D9S1748). The primer sequences are available through the Genome Database (<http://www.gdb.org>). Linkage analyses were carried out using the LINKMAP program of the LINKAGE package.³⁴ The disease locus was moved across the following fixed map: D9S736 – 0.003 cM – D9S1749 – 0.011 cM – D9S942 – 0.00003 cM – D9S1748. LOD scores were calculated in each of the families studied assuming a

dominant model for the disease gene with a disease allele frequency of 0.0001. Reduced penetrances in males and females were assumed according to preliminary analyses (Florence Demeais, unpublished data). A LOD score greater than 3.0 indicates evidence for linkage, while a LOD score less than –2 indicates evidence against linkage. No conclusions can be drawn if the LOD score is between –2 and 3.

Diploid to haploid conversion

Haploid converted clones from six index cases of families possibly linked to 9p21 locus (table 1) were created by GMP Genetics by a technique originally described by Yan *et al.*³⁵ Hybrid cells were maintained in DMEM with high glucose including 10% FBS, 0.5 mg/ml Geneticin, 1×HAT, and penicillin-streptomycin, according to the manufacturer's instructions. In order to verify that each haploid converted clone contained only one allele, we compared its haplotype with that of its parental lymphoblastoid cell line using the microsatellite markers D9S1749 and D9S942. The primer sequences are available through the Genome Database (<http://www.gdb.org>) and PCR conditions are described in Auroy *et al.*³³

RT-PCR analysis of *CDKN2A* transcripts

Total RNA was extracted from cell lines that were haploid for chromosome 9 using the Tri-Reagent kit (Sigma). To

Table 1 Molecular analysis at 9p21 locus

Clinical subgroups	p15		p14 ^{ARF}		p16 ^{INK4A}		p16 ^{INK4A} promoter		Deep intronic mutation		LOD score at D9S942	cDNA haploid cell p16INK4a and p14ARF			
	Exon 1 and 2	Ratio p15/Alb	SD	Exon 1β	Ratio p14 ^{ARF} /Alb	SD	Exon 1α, 2, 3	Ratio p16 ^{INK4A} /Alb	SD	-34G>T			IVS2-105A>G		
A	CMM families of at least 3 cases	WT	0.98	0.08	WT	1.08	0.09	WT	1.05	0.07	WT	ND	ND		
		WT	1.01	0.06	WT	1.06	0.05	WT	1.13	0.06	WT	-1.091	Normal		
		WT	0.98	0.07	WT	1.00	0.05	WT	1.05	0.04	WT	-1.732	ND		
		WT	1.04	0.06	WT	0.95	0.13	WT	0.92	0.07	WT	-0.513	No LCL		
		WT	1.11	0.08	WT	1.06	0.01	WT	1.07	0.01	WT	0.342	Normal		
		WT	1.20	0.04	WT	1.04	0.06	WT	0.95	0.06	WT	0.618	Normal		
		WT	1.08	0.05	WT	1.14	0.03	WT	1.08	0.03	WT	ND	ND		
		WT	0.89	0.10	WT	0.93	0.06	WT	1.02	0.07	WT	ND	ND		
		WT	1.13	0.02	WT	1.06	0.03	WT	1.06	0.02	WT	ND	ND		
		WT	1.02	0.07	WT	1.06	0.01	WT	0.99	0.02	WT	-0.201	Normal		
		WT	1.18	0.05	WT	1.06	0.04	WT	1.13	0.05	WT	Unlinked*	ND		
		WT	0.88	0.06	WT	0.97	0.06	WT	0.99	0.05	WT	0.292	Normal		
		WT	1.12	0.04	WT	1.15	0.03	WT	1.05	0.04	WT	-2.556	ND		
		WT	1.03	0.04	WT	0.99	0.003	WT	1.13	0.004	WT	0.539	Normal		
		WT	1.09	0.05	Deletion**	0.56	0.03	WT	1.18	0.04	ND	ND	ND		
		Two cases including MPM	WT	1.06	0.04	WT	1.09	0.08	WT	1.01	0.05	WT	ND	ND	
	WT		1.01	0.04	WT	1.07	0.03	WT	1.12	0.03	WT	ND	ND		
	WT		1.04	0.05	WT	1.12	0.06	WT	1.02	0.05	WT	ND	ND		
	WT		1.14	0.03	WT	1.05	0.06	WT	1.10	0.08	WT	ND	ND		
	WT		1.04	0.04	WT	1.08	0.07	WT	1.04	0.07	WT	ND	ND		
	WT		1.12	0.03	WT	1.09	0.04	WT	1.08	0.03	WT	ND	ND		
	WT		0.86	0.05	WT	1.00	0.02	WT	0.86	0.08	WT	ND	ND		
	MPM		WT	1.08	0.05	WT	1.02	0.05	WT	0.98	0.02	WT	ND	ND	
		WT	0.93	0.04	WT	0.99	0.03	WT	0.93	0.04	WT	ND	ND		
WT		1.02	0.00	WT	0.91	0.08	WT	0.92	0.05	WT	ND	ND			
WT		0.97	0.05	WT	1.08	0.06	WT	1.03	0.06	WT	ND	ND			
WT		1.14	0.05	WT	1.17	0.05	WT	1.04	0.05	WT	ND	ND			
WT		1.10	0.04	WT	1.07	0.09	WT	1.00	0.04	WT	ND	ND			
WT		1.06	0.06	WT	1.04	0.08	WT	1.05	0.04	WT	ND	ND			
WT		1.14	0.05	WT	1.08	0.06	WT	1.04	0.06	WT	ND	ND			
B.	CMM and NST	WT	1.08	0.10	WT	1.04	0.08	WT	1.10	0.08	WT	ND	ND		
		WT	0.98	0.04	WT	1.00	0.04	WT	1.03	0.04	WT	ND	ND		
		WT	1.05	0.01	WT	1.04	0.02	WT	1.02	0.04	WT	ND	ND		
		WT	0.96	0.04	WT	0.99	0.03	WT	1.00	0.03	WT	ND	ND		
		WT	1.07	0.05	WT	1.10	0.02	WT	0.99	0.03	WT	ND	ND		
		WT	1.12	0.07	WT	1.07	0.04	WT	0.96	0.06	WT	ND	ND		
		Family no. 1361	WT	1.06	0.08	WT	0.96	0.06	WT	0.99	0.04	ND	ND	ND	
			WT	0.99	0.08	WT	0.92	0.09	WT	0.89	0.06	ND	ND	ND	
			WT	1.06	0.13	WT	0.89	0.06	WT	0.93	0.04	ND	ND	ND	
			WT	0.91	0.13	WT	0.94	0.06	WT	0.90	0.04	ND	ND	ND	
			WT	1.01	0.09	WT	1.00	0.10	WT	0.95	0.05	ND	ND	ND	
			WT	0.96	0.08	WT	1.01	0.05	WT	0.89	0.06	ND	ND	ND	
			Family no. 10754	WT	0.92	0.07	301G>A _v	1.02	0.02	WT	0.89	0.07	ND	ND	ND
				WT	0.87	0.04	G16D	1.06	0.06	WT	0.92	0.04	ND	ND	ND

Table 1 Continued

Clinical subgroups	p15		p14 ^{ARF}		p16 ^{INK4A}		p16 ^{INK4A} promoter		Deep intronic mutation		LOD score at D9S942	cDNA haploid cell p16 ^{INK4A} and p14ARF
	Exon 1 and 2	Ratio p15/Alb	SD	Exon 1β	Ratio p14 ^{ARF} /Alb	SD	Exon 1α, 2, 3	Ratio p16 ^{INK4A} /Alb	SD	IVS2-105A>G		
C. Li-Fraumeni like	Family no. 10976	1.04	0.03	WT	0.97	0.08	WT	0.92	0.05	ND	ND	ND
	Family no. 10811	0.96	0.05	WT	0.93	0.04	WT	0.93	0.06	ND	ND	ND
	Family no. 3272	1.06	0.02	WT	0.88	0.08	WT	0.87	0.06	ND	ND	ND
	Family no. 11400	0.89	0.02	WT	0.81	0.06	WT	0.83	0.03	ND	ND	ND
	Family no. 10579	1.04	0.05	WT	1.00	0.02	WT	1.06	0.02	ND	ND	ND
	Family no. 10581	0.83	0.09	WT	0.96	0.07	WT	0.99	0.05	ND	ND	ND
	Family no. 10580	1.03	0.02	WT	0.99	0.02	WT	0.99	0.02	ND	ND	ND
	Family no. 10583	1.00	0.07	WT	0.98	0.05	WT	0.96	0.03	ND	ND	ND
	Family no. 10578	1.01	0.04	WT	1.01	0.07	WT	1.17	0.06	ND	ND	ND

*It should be noted that in family no. 571 (group A), the disease gene was linked with the 1p22 region.³⁶

**847/4 bp.

ND, not determined; SD, standard deviation calculated using the standard curve method (ABI Prism 7700 Sequence Detection System, User Bulletin#2).

eliminate genomic DNA contamination, RNA samples were treated with DNase in a final volume of 100 µl, under the following conditions: 20 µg total RNA, 40 U RNase inhibitor (Invitrogen, Carlsbad, CA), 40 U RNase-free DNase I (Roche Diagnostics, Meylan, France), 5 mM MgCl₂, and 5 mM Tris-HCl pH 7.5. The DNase reaction was performed at 37°C for 1 h, followed by phenol/chloroform extraction and precipitation with 3 M sodium acetate and ethanol.

The reverse transcription reaction was performed using 2 µg of total RNA with 100 U Superscript II reverse transcriptase (Gibco-BRL Life Technologies, Carlsbad, CA) and 50 pmol of random primers in a final volume of 20 µl, for 50 min at 42°C. A 1 µl sample of each reverse transcription reaction product was amplified by long range PCR with the Long Template PCR System kit (Roche Molecular Biochemicals, Mannheim, Germany) and using primers specific for the p16^{INK4A} and p14^{ARF} cDNAs (appendix A). Reaction conditions were as described in the Expand Long Template PCR System protocol, with an annealing temperature of 68°C and system 3.

RESULTS

A comprehensive analysis of the 9p21 locus was performed on our three groups of patients (table 1). The first group (36 cases) comprised CMM kindreds and patients with MPM; the second group consisted of 12 families with CMM+NST; and the third group of five families had features of LFS, including a melanoma case, but without p53 germline mutations.

A germline deletion affecting ARF exon 1β

We investigated whether the 9p21 locus was affected by germline deletions by quantifying the copy number of the *CDKN2B*, *CDKN2A*, and *ARF* genes by real time PCR. In all index cases tested from the three clinical groups, we observed two copies of *CDKN2A* and *CDKN2B* (table 1). However, with a probe located close to exon 1β of p14^{ARF} (184 bp) we found only a single copy in two melanoma affected patients (FG7617 and FG7381) from a family with five cases of CMM (fig 1A). As the probe is 19 kb proximal to exon 1α of *CDKN2A*, these findings suggested the presence of a germline deletion affecting *ARF* but not *CDKN2A* or *CDKN2B*. This was confirmed by haplotype analysis on patients FG7617 and FG7381 with microsatellite markers spanning the 9p21 region. Two markers were potentially homozygous: D9S1748, which is 300 bp distal to *ARF* exon 1β, and D9S974 which is 7 kb distal to *ARF* exon 1β and 13 kb proximal to *CDKN2A* exon 1α (fig 1B).

To characterise the deletion in more detail, we performed long range PCR amplification of genomic DNA from patient FG7617 and a normal control using primers that encompass p14^{ARF} exon 1β and the two microsatellite markers D9S1748 and D9S974. The expected 22 kb product was observed with both DNA samples plus an additional 14 kb band specific for patient F7617 (data not shown). Mapping of this shorter DNA fragment with the restriction enzymes *SpeI* and *BglII* gave an indication of the boundaries of the deletion and new primers were designed to locate the exact breakpoints. Sequencing of the resulting PCR product showed that the germline deletion extended for 8474 bp beginning at 196 bp upstream of the initiation codon of p14^{ARF} exon 1β and ending at 11233 bp upstream of p16^{INK4A} exon 1α (fig 1C,D). An identical deletion occurred in patient FG7381.

A germline missense mutation in ARF exon 1β

We did not detect germline mutations in exons 1α, 2, and 3 of *CDKN2A* and exons 1 and 2 of *CDKN2B* in any of the patients tested (table 1). We did however find one heterozygote germline mutation in exon 1β of p14^{ARF} in a patient (II-3) who developed a cutaneous melanoma at the age of 45 (fig 2). The G>A missense mutation (fig 2B) results in the substitution of glycine by aspartic acid at codon 16 (G16D). This individual belongs to

Figure 2 (A) Pedigree of the CMM+NST family no. 10754. Black squares indicate melanoma affected patients and stripes indicate the individual with other cancers. The tumours and genotypes are indicated below the symbol and the number of melanomas is indicated in brackets. Stars indicate the patients who have been tested. (B) $p14^{ARF}$ exon 1 β partial sequences of a normal control (top) and of index case III-3 displaying the G16D heterozygote germline mutation. (C) Functional analysis of the G16D variant of $p14^{ARF}$: MDM2 binding and p53 stabilisation by the G16D variant of $p14^{ARF}$. U2OS cells were transfected with vectors encoding MDM2 and GFP-ARF or the G16D derivative as indicated. GFP alone was used as a control. After 48 h, lysates were immunoprecipitated with a polyclonal antibody against $p14^{ARF}$ (JR14), fractionated by SDS-PAGE in a 12% gel, and immunoblotted for MDM2 and GFP. There was no difference in the amount of MDM2 co-precipitated with wildtype or mutant $p14^{ARF}$. (D) U2OS cells were transfected with the indicated combinations of p53, MDM2, and GFP-ARF plasmids. Samples (50 μ g) of total protein were fractionated by SDS-PAGE and immunoblotted for p53 and GFP. The ability of MDM2 to promote degradation of p53 (lane 3) is blocked by the presence of either wildtype (lane 4) or the G16D variant of $p14^{ARF}$ (lane 5).

an astrocytoma-melanoma syndrome family with two cases of CMM (fig 2A). Subsequent investigation of this family showed that the proband's brother (II-2), who developed CMM at the age of 50, is an obligate carrier of the G16D mutation because his daughter tested positive for the mutation. Unexpectedly, the

sister (II-1), who developed breast cancer and a meningioma, does not carry the G16D mutation, casting some doubt on its association with cancer predisposition. However, as the mutation was not observed in 202 control individuals, it cannot be regarded as a common polymorphism (data not shown).

To try to ascertain the functional relevance of the G16D mutation, we substituted the relevant nucleotide in p14^{ARF} cDNA by site directed mutagenesis, and examined the ability of the altered protein to interact with MDM2 and to block the MDM2 mediated degradation of p53. It has been reported that the amino-terminal region of p14^{ARF} is largely responsible for the interaction with MDM2, and for the localisation of p14^{ARF} in the nucleolus.^{37, 38} However, a form of p14^{ARF} that lacks the amino-terminal 20 residues is still able to function normally.³⁸ As shown in fig 2C, the G16D variant, expressed as a fusion protein with GFP, retained the ability to interact with MDM2 as judged by co-immunoprecipitation with a p14^{ARF} specific antibody. Moreover, the G16D variant and wildtype p14^{ARF} showed the same ability to prevent the MDM2 mediated turnover of p53 in a standard transient transfection assay (fig 2D). At a gross level, therefore, the G16D variant is functional, but the available assays are not suitable enough to detect subtle changes in p14^{ARF} activity.

An indirect indication of the significance of G16D would be if a "second hit" occurred somatically in the wildtype allele of *ARF* in the tumour cells of the affected patients. However, we did not detect loss of heterozygosity or somatic mutation in exon 1β in the primary melanoma of individual II-3 or in the metastases of individual II-2 (data not shown).

Analysis of non-coding regions of 9p21

As the majority of the CMM prone families (group A) showed no evidence of germline alterations in the coding exons of *CDKN2A*, *CDKN2B*, and *ARF*, we considered the possibility that the underlying germline defect could be located in non-coding regions (promoter, intron) and affect the expression, structure, or stability of the respective transcripts. We therefore screened for the presence of the known recurrent deep intronic mutation (IVS2-105A>G) and for the -34G>T mutation in the *CDKN2A* promoter. Neither mutation was detected in any of the index cases from group A (table 1).

9p21 linkage analysis

We then analysed linkage to the 9p21 locus in nine families with three or more melanoma cases (group A) using the microsatellite markers D9S736, D9S1749 (*CDKN2A*), D9S942, and D9S1748 (table 1). For one of the nine families (no. 10279), the disease gene was unlinked to the 9p21 region (LOD score <-2). For one family (no. 3324), there was a suggestion of independence between the disease gene and the 9p21 region (-1.8<LOD score<-1.2), while the results for the seven other families (nos. 10339, 3026, 2535, 9849, 1403, 9834, 3284) were inconclusive (-1.2<LOD scores<0.7). It should be noted that in a tenth family (family no. 571) for which linkage at 9p21 locus was not performed in the present study, the disease gene was linked to the recently identified 1p22 locus.³⁶

Haploid cell analysis of CDKN2A/ARF transcripts

In six out seven families for which linkage analysis was not conclusive (group A), we were able to obtain lymphoblastoid cell lines and generate somatic cell hybrids carrying separate 9p21 alleles (through GMP Genetics). Diploid to haploid conversion facilitates the detection and interpretation of abnormal transcripts. In each case, we selected two haploid clones carrying distinct alleles of chromosome 9, as judged using the D9S1749 and D9S942 markers (data not shown). Long range RT-PCR performed for both p16^{INK4A} and p14^{ARF} transcripts revealed only normally sized bands and therefore no aberrant transcripts.

DISCUSSION

We undertook a comprehensive survey of the 9p21 region in a series of 53 melanoma prone families and individuals,

including 36 index cases that in a routine screen had shown no detectable germline mutations in the coding exons of *CDKN2A* or *CDK4* (exon 2). Using a combination of DNA sequencing, quantitation of gene copy number by real time PCR, LOH analyses of microsatellite markers, and transcript analyses in haploid somatic cell hybrids, we found no evidence for germline alterations in either the coding or non-coding domains of *CDKN2A* and *CDKN2B*. However, two cases showed germline abnormalities that specifically affected *ARF*.

The first was the G16D missense mutation in exon 1β, detected in a CMM+NST family. Although the pedigree of this family implies that the mutation was present in two brothers who developed CMM, it was not present in a sister who developed meningioma and breast cancer. Association with melanoma-neural system tumour predisposition therefore remains ambiguous, as does the impact of the mutation on p14^{ARF} function. G16D lies within the most conserved region of p14^{ARF} and in a domain that interacts with MDM2,³⁷ but the mutation had no discernible effect on the ability of p14^{ARF} to bind to HDM2 or to stabilise p53, at least as assessed using the available assays. As these assays rely on transient co-expression of exogenous proteins, they do not allow us quantitative measurements of relatively subtle changes. Analysis of the primary melanoma and metastasis from the two brothers provided no evidence for a second somatic event affecting p14^{ARF} exon 1β. However, we have not excluded the possibility that the wildtype *ARF* allele has been silenced by promoter methylation, as described in other studies.^{39, 40} In conclusion, either the G16D mutation represents a p14^{ARF} loss of function mutation and this family does not have hereditary CMM+NST assuming that the meningioma is a sporadic tumour or the G16D mutation represents a rare variant without functional consequence and the combination of CMM+NST is caused by some other unknown genetic defect.

The second alteration, found in a family with five documented CMM cases, was a large germline deletion that encompassed p14^{ARF} exon 1β. By mapping the deletion breakpoints we found that it ended >11.2 kb upstream of the initiation codon of p16^{INK4A} and was therefore highly unlikely to affect the expression of p16^{INK4A}. There has been an ongoing debate as to whether the combined loss of p14^{ARF} and p16^{INK4A} function is responsible for the CMM+NST syndrome. Large deletions encompassing both *CDKN2A* and *ARF* and a splicing mutation that affects processing of both the p16^{INK4A} and p14^{ARF} RNA transcripts have been described in three CMM+NST families.^{14, 15} The deletion we describe here only affects *ARF* exon 1β and occurred in a melanoma prone family without evidence of NSTs. Our findings therefore suggest that germline deletions specifically affecting p14^{ARF} are not responsible for NST susceptibility. Predisposition to CMM+NST could either be due to complete disruption of the *CDKN2A* locus or be the result of more complex genetic inheritance. Our data also reinforce the hypothesis that *ARF* is indeed a melanoma susceptibility gene as argued in other studies.^{17, 18}

What explanation can be proposed for the other 50 cases in which we failed to find germline alterations by any of the methods used. Seven families from group A (nos. 10339, 3026, 2535, 9849, 1403, 9834, 10279) gave equivocal results, leaving open the possibility of linkage to 9p21. Our survey would not have revealed single nucleotide changes or small deletions or insertions in non-coding regions which have not been previously recorded. Such changes could in principle affect gene expression, for example by altering the binding of protein complexes that determine chromatin conformation in response to various stimuli. Finally, several previous studies have proposed that there are additional tumour suppressor genes in the chromosome 9p21 region that are implicated in melanoma. LOH studies have suggested at least two loci, one

telomeric to *IFNA* and one centromeric to D9S171⁴¹ (reviewed in Pollock *et al*⁴²), and there are potential candidate genes that may warrant consideration, such as *TUSC1* (tumour suppressor candidate 1)⁴³ and *MTAP* (methylthioadenosine phosphorylase).⁴⁴ It is noteworthy that there are recent reports of *MTAP* being deleted or silenced in melanoma⁴⁵ as well as pancreatic cancer.⁴⁶

In addition to the seven families which gave equivocal results, haplotype analysis revealed that at least three of the families (nos. 3324, 571, 10279) showed no evidence for a linkage to chromosome 9p21, suggesting that there are additional melanoma susceptibility genes. A recent genome-wide scan for linkage has been performed in a set of families with three or more CMM cases originating from Australia. Results provided evidence for linkage to the 1p22 region, strongest in families with the earliest mean age at diagnosis, giving therefore significant evidence of a novel melanoma susceptibility gene located at 1p22.³⁶ Linkage to 1p36 has also been reported in North American melanoma kindreds.⁴⁷ However, it should be mentioned that no melanoma susceptibility genes have been identified at these loci to date.

ACKNOWLEDGEMENTS

We thank Blandine Passinge-Dumas, Danièle Pham, and Antoine Piriou for technical assistance.

ELECTRONIC-DATABASE INFORMATION

The GDB Human Genome Database can be found at <http://www.gdb.org>.

Authors' affiliations

K Laud, C Marian, M Barrois, G M Lenoir, B Bressac-de Paillerets, Service de Génétique, Institut Gustave Roussy, 94800 Villejuif, France
M F Avril, Service de Dermatologie, Institut Gustave Roussy, 94800 Villejuif, France
A Chompret, Département de Médecine, Institut Gustave Roussy, 94800 Villejuif, France
A M Goldstein, M A Tucker, Genetic Epidemiology Branch, Division of Cancer, Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
P A Clark, G Peters, Cancer Research UK, London Research Institute, Lincoln's Inn Fields Laboratories, London, WC2A 3PX, UK
V Chaudru, F Dumenais, INSERM-Université d'Evry, EMI0006, 91034 Evry, France
A Spatz, Service d'Anatomopathologie, Institut Gustave Roussy, 94800 Villejuif, France
M W Smith, Laboratory of Genomic Diversity, Center for Cancer Research and Basic Research Program, SAIC Frederick, National Cancer Institute at Frederick, NIH, DHHS, Frederick, MD 21702, USA

This work was supported by a grant from the Association pour la Recherche contre le Cancer (ARC), Subvention libre 1998, a Programme Hospitalier de Recherche Clinique (PHRC) Regional 2001 (AOR 01 091). KL is a recipient of a postdoctoral fellowship from Institut Gustave Roussy (CRC 2001). CM was a recipient of a Marie Curie fellowship (contract QLGA-1999-50406)

Competing interests: none declared

*The following French Hereditary Melanoma Study Group members participated in this study: Valérie Arigon, Bertrand Bachollet, Françoise Boitier, Jean Pierre Cesarini, Liliane Demange, Nicolas Janin, Pascal Joly, and Michel Longy

Note added in proof: After submission of this manuscript, the results of a new mutation scanning by direct sequencing were obtained for all familial cases from group A (n = 14) except for family FG7617 carrying the deletion. We detected a *CDKN2A* germline mutation for index case no. 1772, c.104G>T, p.Gly35Val

REFERENCES

- Cannon-Albright LA,** Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade OI, Diaz MO, Kwiatkowski DJ, Piepkorn MW, Zone JJ, Skolnick MH. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. *Science* 1992;258:1148-52.
- Sharpless NE,** DePinho RA. The INK4A/ARF locus and its two gene products. *Curr Opin Genet Dev* 1999;9(1):22-30.
- Bishop DT,** Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorsio P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA. Geographical variation in the penetrance of CDKN2A mutations for melanoma. *J Natl Cancer Inst* 2002;94(12):894-903.
- Hussussian CJ,** Struwing JP, Goldstein AM, Higgins PAT, Ally DS, Steahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. *Nat Genet* 1994;8:15-21.
- Rutter JL,** Goldstein AM, Davila MR, Tucker MA, Struwing JP. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. *Oncogene* 2003;22(28):4444-8.
- Loo JC,** Liu L, Hao A, Gao L, Agatep R, Shennan M, Summers A, Goldstein AM, Tucker MA, Deters C, Fusaro R, Blazer K, Weitzel J, Lassam N, Lynch H, Hogg D. Germline splicing mutations of CDKN2A predispose to melanoma. *Oncogene* 2003;22(41):6387-94.
- Harland M,** Mistry S, Bishop DT, Newton Bishop JA. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. *Hum Mol Genet* 2001;10(23):2679-82.
- Liu L,** Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. *Nat Genet* 1999;21(1):128-32.
- Quelle DE,** Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16^{INK4a} but not by the alternative reading frame protein p19^{ARF}. *Proc Natl Acad Sci U S A* 1997;94:669-73.
- Kim SH,** Mitchell M, Fujii H, Llanos S, Peters G. Absence of p16INK4a and truncation of ARF tumor suppressors in chickens. *Proc Natl Acad Sci U S A* 2003;100(1):211-16.
- Hashemi J,** Lindstrom M, Asker C, Platz A, Hansson J, Wiman K. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. *Cancer Lett* 2002;180(2):211.
- Rizos H,** Darmanian AP, Holland EA, Mann GJ, Kefford RF. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. *J Biol Chem* 2001;276(44):41424-34.
- Zhang Y,** Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. *Mol Cell* 1999;3(5):579-91.
- Bahuau M,** Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. *Cancer Res* 1998;58(11):2298-303.
- Petronzelli F,** Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. *Genes Chromosomes Cancer* 2001;31(4):398-401.
- Randerson-Moor JA,** Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton BJ, Bishop DT. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. *Hum Mol Genet* 2001;10(1):55-62.
- Hewitt C,** Lee WC, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N. Germline mutation of ARF in a melanoma kindred. *Hum Mol Genet* 2002;11(11):1273-9.
- Rizos H,** Puig S, Badenas C, Malvey J, Darmanian AP, Jimenez L, Mila M, Kefford RF. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. *Oncogene* 2001;20(39):5543-7.
- Krimpenfort P,** Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. *Nature* 2001;413(6851):83-6.
- Platz A,** Hansson J, Manasson-Brahme E, Lagerlöf B, Linder S, Lundqvist E, Sevigny P, Inganäs M, Ringborg U. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. *J Nat Cancer Inst* 1997;89:697-702.
- Flores JF,** Pollock PM, Walker GJ, Glendening JM, Lin AH, Palmer JM, Walters MK, Hayward NK, Fountain JW. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. *Oncogene* 1997;15(24):2999-3005.
- Stone S,** Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A. Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. *Oncogene* 1995;11:987-91.
- Liu L,** Goldstein AM, Tucker MA, Brill H, Gruis NA, Hogg D, Lassam NJ. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. *Genes Chromosomes Cancer* 1997;19(1):52-4.
- Platz A,** Sevigny P, Norberg T, Ring P, Lagerlöf B, Ringborg U. Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. *Br J Cancer* 1996;74(6):936-41.
- Matsumura Y,** Nishigori C, Yagi T, Imamura S, Takebe H. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma. *Arch Dermatol Res* 1998;290(4):175-80.

- 26 **Laurendeau I**, Bahuu M, Vodovar N, Larramendy C, Olivi M, Bieche I, Vidaud M, Vidaud D. TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency. *Clin Chem* 1999;**45**(7):982–6.
- 27 **Brugieres L**, Gardes M, Moutou C, Chompret A, Meresse V, Martin A, Poisson N, Flamant F, Bonaitipellie C, Lemerle J, Feunteun J. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. *Cancer Res* 1993;**53**:452–5.
- 28 **Kuklin A**, Munson K, Gjerde D, Haefele R, Taylor P. Detection of single-nucleotide polymorphisms with the WAVE DNA fragment analysis system. *Genet Test* 1997;**1**(3):201–6.
- 29 **O'Donovan MC**, Oefner PJ, Roberts SC, Austin J, Hoogendoorn B, Guy C, Speight G, Upadhyaya M, Sommer SS, McGuffin P. Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. *Genomics* 1998;**52**(1):44–9.
- 30 **Liu W**, Smith DI, Rechtzigel KJ, Thibodeau SN, James CD. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. *Nucleic Acids Res* 1998;**26**(6):1396–400.
- 31 **Laud K**, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B. BRAF as a melanoma susceptibility candidate gene? *Cancer Res* 2003;**63**(12):3061–5.
- 32 **Barrois M**, Bieche I, Mazoyer S, Champeme MH, Bressac-de Paillerets B, Lidereau R. Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. *Clin Genet* 2004;**65**(2):131–6.
- 33 **Auroy S**, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, Frebourg T, Joly P, Spatz A, Rubino C, Demenais F, Bressac-de Paillerets B. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. *Genes Chromosomes Cancer* 2001;**32**(3):195–202.
- 34 **Lathrop GM**, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. *Proc Natl Acad Sci U S A* 1984;**81**(11):3443–6.
- 35 **Yan H**, Papadopoulos N, Marra G, Perra C, Jiricny J, Boland CR, Lynch HT, Chadwick RB, de la Chapelle A, Berg K, Eshleman JR, Yuan W, Markowitz S, Laken SJ, Lengauer C, Kinzler KW, Vogelstein B. Conversion of diploidy to haploidy. *Nature* 2000;**403**(6771):723–4.
- 36 **Gillanders E**, Hank Joo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN, Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J. Localization of a novel melanoma susceptibility locus to 1p22. *Am J Hum Genet* 2003;**73**(2):301–13.
- 37 **Lohrum MA**, Ashcroft M, Kubbutat MH, Vousden KH. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. *Curr Biol* 2000;**10**(9):539–42.
- 38 **Clark PA**, Llanos S, Peters G. Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. *Oncogene* 2002;**21**(29):4498–507.
- 39 **Robertson KD**, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. *Mol Cell Biol* 1998;**18**(11):6457–73.
- 40 **Yin D**, Xie D, Hofmann WK, Miller CW, Black KL, Koeffler HP. Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. *Oncogene* 2002;**21**(54):8372–8.
- 41 **Palmieri G**, Cossu A, Ascierto PA, Botti G, Strazzullo M, Lissia A, Colombino M, Casula M, Floris C, Tanda F, Pirastu M, Castello G. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. *Br J Cancer* 2000;**83**(12):1707–14.
- 42 **Pollock PM**, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. *Cancer Res* 2001;**61**(3):1154–61.
- 43 **Shan Z**, Parker T, Wiest JS. Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer. *Oncogene* 2004;**23**(39):6612–20.
- 44 **Schmid M**, Sen M, Rosenbach MD, Carrera CJ, Friedman H, Carson DA. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. *Oncogene* 2000;**19**(50):5747–54.
- 45 **Behrmann I**, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, Bosserhoff AK. Characterization of methylthioadenosine phosphorylase (MTAP) expression in malignant melanoma. *Am J Pathol* 2003;**163**(2):683–90.
- 46 **Subhi AL**, Tang B, Balsara BR, Altomare DA, Testa JR, Cooper HS, Hoffman JP, Meropol NJ, Kruger WD. Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. *Clin Cancer Res* 2004;**10**(21):7290–6.
- 47 **Goldstein A**, Goldin LR, Dracopoli NC, Clark WH, Tucker MA. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. *Am J Hum Genet* 1996;**58**:1050–6.

Appendix A

Table A1 Primer sequences for PCR and sequencing, primers and probe sequences for RQ-PCR, primer sequences for PCR long range, and dHPLC conditions

Exon		Primer sequences	Product size (bp)	dHPLC temperature (°C)
CDKN2B exon 1	F	5'-GGAAAGAAGGGAAGAGTGTCTGTAAG-3'	349	58–69
	R	5'-TAACGGAGACTCTGTACAAATCTACA-3'		
CDKN2B exon 2	F	5'-CCACCTCTGGCTCTGACCAC-3'	380	57–63–69
	R	5'-CAGCCTTCATCGAATTAGGT-3'		
ARF exon 1β	F	5'-CGTGGGTCCAGTCT-3'	366	61–68
	R	5'-ATCTGTTTACGAAATCACAC-3'		
CDKN2A exon 1α	F	5'-GAAGAAAGAGGAGGGGCTG-3'	340	64–69
	R	5'-GCGCTACCTGATTCGAATTC-3'		
CDKN2A exon 2-1	F	5'-GGGGCTGTGTGGGGTCTG-3'	247	64–68
	R	5'-CAGCACCACGCGTGTCT-3'		
CDKN2A exon 2-2	F	5'-GACCCCGCCTCTCACC-3'	308	63–69
	R	5'-GTGCTGGAAATGAATGCTCTG-3'		
CDKN2A exon 3	F	5'-CGGTAGGACGGCAAGAGAG-3'	169	59–60
	R	5'-CCTGTAGGACCTTCGGTGACTGA-3'		
CDKN2A promoter	F	5'-GAGCCAGTCTCTCTCTTGC-3'	334	
	R	5'-CGCCGCCGCTGCCTGCT-3'		
CDKN2A IVS2-105A/G	F	5'-CAGCGCGGAGTGGAC-3'	353	
	R	5'-AAACTACGAAAGCGGGTGG-3'		
CDKN2B RQ-PCR	F	5'-GGAAAGAAGGGAAGAGTGTCTGTT-3'	85	
	R	5'-CGCGCATTCCGACG-3'		
ARF RQ-PCR	F	5'-GGTCTCGCAGTACCATGAA-3'	72	
	R	5'-TGTTGCTCAGTTTCCCA-3'		
CDKN2A RQ-PCR	P	5'-CTCCCTTCACACAGCCCTCAATC-3'	180	
	F	5'-GGCTGGCTGGTCACAGCA-3'		
cDNA of p16 ^{INK4A} exon 2	R	5'-CGCCCGCACCTCTCTAC-3'	318	
	P	5'-ATGGAGCTTCGGCTGACTGGCT-3'		
cDNA of p16 ^{INK4A} exon 1	F	5'-GACCCCGCCTCTCACC-3'	409	
	R	5'-CCTGTAGGACCTTCGGTGACTGA-3'		
cDNA p14 ^{ARF}	F	5'-CGCCAGCACCAGGGAAGAA-3'	657	
	R	5'-CAGCACCACGCGTGTCT-3'		
9p21 g. Del.1	F	5'-GAGGTCCGGTGGGAGTGGG-3'	22.2 kb	
	R	5'-GAAAGCGGGTGGGTTGTGG-3'		
9p21 g. Del.2	F	5'-CCCACTCCACAGATAGCA-3'	8899	
	R	5'-TGGAACTCAAAGACACGCAAAG-3'		
	F	5'-GCTCAGAGCCGTTCCGAGA-3'		
	R	5'-GGGTTCACAACTGTC-3'		